The combination of dalpiciclib, pyrotinib, and endocrine therapy appears to be clinically active in ER-positive, HER2-positive advanced breast cancer, with a manageable safety profile, albeit in a relatively small patient cohort. This evidence concerns the gene ESR1 and breast cancer.